Intas Pharmaceuticals

Organisation

Funded papers

Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study)
5 Aug 2026

Sources: api.crossref.org

Named in competing interests

Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
Consulting or advice, Fees or honoraria, Grants or research support, 13 Aug 2026
Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study)
Employment, 5 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov